A Digital Educational Intervention With Wearable Activity Trackers to Support Health Behaviors Among Childhood Cancer Survivors: Pilot Feasibility and Acceptability Study.
activity tracker
behavior change
childhood cancer
eHealth
education
exercise
physical activity
survivorship
Journal
JMIR cancer
ISSN: 2369-1999
Titre abrégé: JMIR Cancer
Pays: Canada
ID NLM: 101666844
Informations de publication
Date de publication:
17 Aug 2022
17 Aug 2022
Historique:
received:
30
03
2022
accepted:
13
07
2022
revised:
05
07
2022
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
Childhood cancer survivors are at increased risk of cardiometabolic complications that are exacerbated by poor health behaviors. Critically, many survivors do not meet physical activity guidelines. The primary aim was to evaluate the feasibility and acceptability of iBounce, a digital health intervention for educating and engaging survivors in physical activity. Our secondary aims were to assess the change in survivors' physical activity levels and behaviors, aerobic fitness, and health-related quality of life (HRQoL) after participating in the iBounce program. We recruited survivors aged 8 to 13 years who were ≥12 months post cancer treatment completion. The app-based program involved 10 educational modules, goal setting, and home-based physical activities monitored using an activity tracker. We assessed objective physical activity levels and behaviors using cluster analysis, aerobic fitness, and HRQoL at baseline and after the intervention (week 12). Parents were trained to reassess aerobic fitness at home at follow-up (week 24). In total, 30 participants opted in, of whom 27 (90%) completed baseline assessments, and 23 (77%) commenced iBounce. Our opt-in rate was 59% (30/51), and most (19/23, 83%) of the survivors completed the intervention. More than half (13/23, 57%) of the survivors completed all 10 modules (median 10, IQR 4-10). We achieved a high retention rate (19/27, 70%) and activity tracker compliance (15/19, 79%), and there were no intervention-related adverse events. Survivors reported high satisfaction with iBounce (median enjoyment score 75%; ease-of-use score 86%), but lower satisfaction with the activity tracker (median enjoyment score 60%). Parents reported the program activities to be acceptable (median score 70%), and their overall satisfaction was 60%, potentially because of technological difficulties that resulted in the program becoming disjointed. We did not observe any significant changes in physical activity levels or HRQoL at week 12. Our subgroup analysis for changes in physical activity behaviors in participants (n=11) revealed five cluster groups: most active, active, moderately active, occasionally active, and least active. Of these 11 survivors, 3 (27%) moved to a more active cluster group, highlighting their engagement in more frequent and sustained bouts of moderate-to-vigorous physical activity; 6 (56%) stayed in the same cluster; and 2 (18%) moved to a less active cluster. The survivors' mean aerobic fitness percentiles increased after completing iBounce (change +17, 95% CI 1.7-32.1; P=.03) but not at follow-up (P=.39). We demonstrated iBounce to be feasible for delivery and acceptable among survivors, despite some technical difficulties. The distance-delivered format provides an opportunity to engage survivors in physical activity at home and may address barriers to care, particularly for regional or remote families. We will use these pilot findings to evaluate an updated version of iBounce. Australian New Zealand Clinical Trials Registry ACTRN12621000259842; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12621000259842.
Sections du résumé
BACKGROUND
BACKGROUND
Childhood cancer survivors are at increased risk of cardiometabolic complications that are exacerbated by poor health behaviors. Critically, many survivors do not meet physical activity guidelines.
OBJECTIVE
OBJECTIVE
The primary aim was to evaluate the feasibility and acceptability of iBounce, a digital health intervention for educating and engaging survivors in physical activity. Our secondary aims were to assess the change in survivors' physical activity levels and behaviors, aerobic fitness, and health-related quality of life (HRQoL) after participating in the iBounce program.
METHODS
METHODS
We recruited survivors aged 8 to 13 years who were ≥12 months post cancer treatment completion. The app-based program involved 10 educational modules, goal setting, and home-based physical activities monitored using an activity tracker. We assessed objective physical activity levels and behaviors using cluster analysis, aerobic fitness, and HRQoL at baseline and after the intervention (week 12). Parents were trained to reassess aerobic fitness at home at follow-up (week 24).
RESULTS
RESULTS
In total, 30 participants opted in, of whom 27 (90%) completed baseline assessments, and 23 (77%) commenced iBounce. Our opt-in rate was 59% (30/51), and most (19/23, 83%) of the survivors completed the intervention. More than half (13/23, 57%) of the survivors completed all 10 modules (median 10, IQR 4-10). We achieved a high retention rate (19/27, 70%) and activity tracker compliance (15/19, 79%), and there were no intervention-related adverse events. Survivors reported high satisfaction with iBounce (median enjoyment score 75%; ease-of-use score 86%), but lower satisfaction with the activity tracker (median enjoyment score 60%). Parents reported the program activities to be acceptable (median score 70%), and their overall satisfaction was 60%, potentially because of technological difficulties that resulted in the program becoming disjointed. We did not observe any significant changes in physical activity levels or HRQoL at week 12. Our subgroup analysis for changes in physical activity behaviors in participants (n=11) revealed five cluster groups: most active, active, moderately active, occasionally active, and least active. Of these 11 survivors, 3 (27%) moved to a more active cluster group, highlighting their engagement in more frequent and sustained bouts of moderate-to-vigorous physical activity; 6 (56%) stayed in the same cluster; and 2 (18%) moved to a less active cluster. The survivors' mean aerobic fitness percentiles increased after completing iBounce (change +17, 95% CI 1.7-32.1; P=.03) but not at follow-up (P=.39).
CONCLUSIONS
CONCLUSIONS
We demonstrated iBounce to be feasible for delivery and acceptable among survivors, despite some technical difficulties. The distance-delivered format provides an opportunity to engage survivors in physical activity at home and may address barriers to care, particularly for regional or remote families. We will use these pilot findings to evaluate an updated version of iBounce.
TRIAL REGISTRATION
BACKGROUND
Australian New Zealand Clinical Trials Registry ACTRN12621000259842; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12621000259842.
Identifiants
pubmed: 35976683
pii: v8i3e38367
doi: 10.2196/38367
pmc: PMC9434388
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e38367Informations de copyright
©Lauren Ha, Claire E Wakefield, David Mizrahi, Claudio Diaz, Richard J Cohn, Christina Signorelli, Kalina Yacef, David Simar. Originally published in JMIR Cancer (https://cancer.jmir.org), 17.08.2022.
Références
Int J Behav Nutr Phys Act. 2020 Sep 24;17(1):122
pubmed: 32972439
Pediatr Blood Cancer. 2017 Dec;64(12):
pubmed: 28618158
Res Nurs Health. 2008 Apr;31(2):180-91
pubmed: 18183564
J Health Care Poor Underserved. 2014 May;25(2):901-12
pubmed: 24858893
Med Sci Sports Exerc. 1982;14(5):377-81
pubmed: 7154893
JMIR Mhealth Uhealth. 2016 Nov 23;4(4):e129
pubmed: 27881359
Lancet Oncol. 2019 Jul;20(7):972-983
pubmed: 31129029
Asia Pac J Clin Oncol. 2013 Jun;9(2):99-109
pubmed: 22897920
Transl Behav Med. 2021 Oct 23;11(10):1915-1922
pubmed: 34037786
Rural Remote Health. 2013 Apr-Jun;13(2):2005
pubmed: 23621328
Support Care Cancer. 2009 Apr;17(4):349-57
pubmed: 18543006
PLoS One. 2022 Oct 5;17(10):e0274644
pubmed: 36197890
Crit Rev Oncol Hematol. 2019 Jan;133:129-141
pubmed: 30661649
JMIR Mhealth Uhealth. 2019 Dec 11;7(12):e14854
pubmed: 31825319
Curr Sports Med Rep. 2011 Nov-Dec;10(6):352-9
pubmed: 22071396
Lancet. 2017 Dec 9;390(10112):2569-2582
pubmed: 28890157
Cancer Nurs. 2013 Sep-Oct;36(5):E9-E16
pubmed: 23963198
Respir Care. 2003 Aug;48(8):783-5
pubmed: 12890299
J Phys Act Health. 2008;5 Suppl 1:S98-111
pubmed: 18364528
Psychooncology. 2019 Jun;28(6):1207-1226
pubmed: 30970149
J Pediatr Hematol Oncol. 2008 Apr;30(4):272-80
pubmed: 18391695
Pediatr Blood Cancer. 2018 Aug;65(8):e27216
pubmed: 29722481
Health Qual Life Outcomes. 2021 Nov 15;19(1):256
pubmed: 34781978
Pediatr Res. 2016 Sep;80(3):338-46
pubmed: 27064243
Cochrane Database Syst Rev. 2016 Mar 31;3:CD008796
pubmed: 27030386
Support Care Cancer. 2018 Jul;26(7):2177-2184
pubmed: 29383508
BMC Pulm Med. 2013 Aug 05;13:49
pubmed: 23915140
Future Child. 1999 Fall;9(2):30-44
pubmed: 10646256
Pediatr Blood Cancer. 2016 Apr;63(4):684-9
pubmed: 26756736
Pediatr Blood Cancer. 2021 Sep;68(9):e29134
pubmed: 34133073
Int J Pediatr. 2011;2011:461512
pubmed: 22121378
BMJ Open Sport Exerc Med. 2018 May 07;4(1):e000322
pubmed: 29765699
Pediatr Blood Cancer. 2017 Feb;64(2):387-394
pubmed: 27615711
J Child Neurol. 2009 Nov;24(11):1455-63
pubmed: 19841433
Crit Rev Oncol Hematol. 2017 Oct;118:27-41
pubmed: 28917267
Psychooncology. 2010 Sep;19(9):997-1003
pubmed: 19918964
Ann Behav Med. 2017 Apr;51(2):226-239
pubmed: 27757789
J Sci Med Sport. 2013 Mar;16(2):124-8
pubmed: 22770768
Rehabil Nurs. 2013 Jan-Feb;38(1):48-59
pubmed: 23365005
J Adolesc Young Adult Oncol. 2021 Feb;10(1):1-14
pubmed: 32897805
J Pediatr Oncol Nurs. 2019 Nov/Dec;36(6):379-389
pubmed: 31271104
Med Sci Sports Exerc. 2014 Apr;46(4):826-33
pubmed: 24121241
Psychooncology. 2005 Nov;14(11):979-91
pubmed: 15744764
Int J Behav Nutr Phys Act. 2022 Jan 6;19(1):2
pubmed: 34991606
J Pediatr Psychol. 2022 Feb 14;47(2):148-157
pubmed: 34865100
Int J Cancer. 2020 Aug 1;147(3):847-855
pubmed: 31800093
Qual Life Res. 2019 Jul;28(7):1951-1961
pubmed: 30739287
Cancer Nurs. 2011 Jan-Feb;34(1):3-12
pubmed: 20706112
Pediatr Blood Cancer. 2019 Oct;66(10):e27922
pubmed: 31309668